|
Smallcap
Recap Archives
May, 2005: American
Pharmaceutical ... Pickups Plus ... HiEnergy Technologies
...VaxGen... HealtheTech ... InterMune ... American Scientific
Resources... Ryerson Tull ... Manhattan Pharmaceuticals
-------------------------------------------------------------------------
. . . Launch leads to record
sales - American Pharmaceutical Partners (Nasdaq: APPX)
reported record first quarter net sales of $120.7 million
for the quarter ended March 31, 2005, a 35% increase over
net sales in the 2004 first quarter. Net income for the quarter
was a quarterly record and gross margin increased to 62.4%
versus 49.8% in the year ago quarter. The company attributes
most of the increase to the launch of ABRAXANE for the treatment
of metastatic breast cancer. American Pharmaceutical Partners
develops injectable pharmaceutical products, focusing on the
oncology, anti-infective and critical care markets.
. . . Chinese Pickup
- Pickups Plus (OTC BB: PUPS) has signed a Letter of
Intent to form a joint venture in the People's Republic of
China which will market and distribute its ValuGard(TM) line
of car care and environmental protection products in the PRC.
The objective is to capitalize on China's growing automobile
industry, which is expected to be on the forefront of the
country's rapid industrialization and modernization. As millions
of Chinese leave their bicycles and take to automobiles, the
car care sector will see rapid growth.
. . . Better Bomb Detection
- HiEnergy Technologies (OTCBB:HIET) has more than doubled
the safety factor of its SIEGMA(TM) 3E3 homemade bomb detector.
The improvement is a result of cutting by more than half the
detector's potential to make "false negative" and
"false positive" identifications from a level of
5% to 2.25%. One of the most dangerous consequences of false
negatives, also known as the "missing fraction,"
is that they lead to a false sense of security. False negative
means that true bombs are mislabeled as non-explosives, and
can increase the chances of fatal accidents. HiEnergy has
recently demonstrated its technology in front of audiences
from the DoD and the FBI. Siemens provides aftermarket maintenance
and servicing for HiEnergy Products.
. . . Mobilizing against
Meningitis - EndoBiologics believes it has developed a
novel and promising technology to treat meningitis. And so
does VaxGen (Pink Sheets: VXGN.PK), so it has formed
a collaboration to pursue research of this new treatment.
VaxGen will fund proof-of-concept studies and has an exclusive
option to continue product development if the studies yield
promising results. Currently there is no licensed vaccine
that has shown protection against a wide range of Meningitis
B strains, a life-threatening disease most common in young
children.
. . . Healthy gain for HealtheTech
- Wellness is doing very well, and by extension, so are some
of the companies providing health measurement tools. 2005
first quarter revenues for HealtheTech (Pink Sheets:
HETC), a maker of proprietary handheld medical devices and
software for the measurement of resting metabolic rate and
nutrition monitoring, increased 64% over the same period last
year. The company attributes the increase to the implementation
of a more targeted strategy addressing commercial fitness,
medically supervised weight management and corporate wellness
markets.
. . . Promising lung drug
study -InterMune (ITMN:Nasdaq) announced results of a
Phase II clinical that showed its experimental drug pirfenidone
successfully delayed the progression of idiopathic pulmonary
fibrosis, an inflammatory lung disease. The disease is characterized
by abnormal formation of lung tissue, causing coughing and
shallow breathing after moderate exercise due to a lack of
oxygen intake from the lungs. There are currently no drugs
approved by the FDA for the treatment of IPF.
. . . More fuel for the
hydrogen movement - Apollo Alternative Fuels Company,
LLC, a wholly-owned subsidiary of Apollo Resources International
(OTCBB:AOOR), has completed a stock purchase agreement with
Energy Ventures Organization, Inc., a pioneer in the fast
growing hydrogen fuels industry. Under the agreement, Apollo
Alternative Fuels owns 50% of the stock in Energy Ventures.
Recent headlines as well as initiatives by the Bush administration
and states such as California have fueled the momentum of
the development of hydrogen as an alternative energy source.
. . . Smarter hearts
- American Scientific Resources (PNK: ASFX) has launched
its flagship Heart Smart System(TM), a line of nutraceutical
products that assist in the successful prevention of cardiovascular
disease. The Heart Smart System(TM) is a nutritional line
of supplements which support and maintain a healthy heart
by rejuvenating the body's supply of Coenzyme Q10 (CoQ10).
The company's product line intersects two major markets in
the healthcare field, nutraceuticals and cardiovascular disease
prevention.
. . . Steelmaker nearly
triples profits - Ryerson Tull (NYSE: RT), a processor
and distributor of steel and other metals, reported that first-quarter
profits nearly tripled and revenue more than doubled. Much
of the increase is attributed to company's acquisition of
Integris Metals. JP Morgan has upgraded Ryerson to an Overweight
rating.
. . . New obesity treatment
- Manhattan Pharmaceuticals (OTCBB: MHTT) has concluded
its Phase 1a trial and begun patient dosing in the Phase 1b
trial to evaluate the safety and tolerability of defined doses
of orally administered Oleoyl estrone (OE) in obese adults.
Oleoyl estrone is believed to be a signaling molecule that
acts on the brain to communicate satiety. It is hypothesized
that in obese individuals circulating OE levels are lower
than would be expected for the level of body fat. Orally administered
formulations of OE has been demonstrated, in extensive preclinical
animal studies, to cause significant weight loss and reduced
caloric consumption without the need for dietary modifications.
|
